Meeting
2023 ASCO Annual Meeting
Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.
Authors
Chenyu Mao
The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Chenyu Mao , Jiong Qian , Yuan Gao , Ying Liu , Tao Zhang , Jiuwei Cui , Yuling Chen , Haonan Chen , Li Zhao , Hongli Wang , Nong Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04085185
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2576)
DOI
10.1200/JCO.2023.41.16_suppl.2576
Abstract #
2576
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
First Author: Nong Xu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
First Author: Ning Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
![A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.](https://d201v5jt9ylckg.cloudfront.net/314/15566/229196/229196_A42_poster_pv.jpg)
A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.
First Author: Zhi Peng
Poster
2023 ASCO Annual Meeting
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
First Author: Ming Liu